Sodium Chloride Symporter Inhibitors
"Sodium Chloride Symporter Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
| Descriptor ID |
D049993
|
| MeSH Number(s) |
D27.505.519.562.812 D27.505.696.560.500.863
|
| Concept/Terms |
Diuretics, Thiazide- Diuretics, Thiazide
- Thiazide Diuretics
- Benzothiadiazine Diuretics
- Diuretics, Benzothiadiazine
|
Below are MeSH descriptors whose meaning is more general than "Sodium Chloride Symporter Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Sodium Chloride Symporter Inhibitors".
This graph shows the total number of publications written about "Sodium Chloride Symporter Inhibitors" by people in this website by year, and whether "Sodium Chloride Symporter Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium Chloride Symporter Inhibitors" by people in Profiles.
-
Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2022 02; 79(2):338-348.
-
Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198.
-
Zinc deficiency induces hypertension by promoting renal Na+ reabsorption. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F646-F653.
-
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenet Genomics. 2018 11; 28(11):251-255.
-
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018 Jun 20; 11(1):55.
-
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
-
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6).
-
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
-
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
-
Genetic Variants Associated With Uncontrolled Blood Pressure on?Thiazide Diuretic/?-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)?and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).